Sterile Injectable Market Estimated To Be Valued US$ 361 Bn in 2016

Global sterile injectable market estimated to be valued US$ 361 Bn in 2016 and poised to grow at CAGR 7.3%. The market for sterile injectable projected to reach US$ 552 Bn by 2023.

Sterile Injectables market report gives a comprehensive outlook on sterile injectable across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report on the sterile injectable market gives historical, current, and future market sizes (US$ Mn) of drug molecules, drug types, disease application, route of administration, end users, and geographic regions. This report studies sterile injectable market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the sterile injectable market report includes drug pipeline analysis, regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analysed sterile injectable market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the sterile injectable market report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of sterile injectables.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-sterile-injectables-market/#ulp-4H8Z4LpNMLEuOnnx


Sterile Injectables Market:

Do the burgeoning product pipelines and drug patent expiries have a positive impact on the market?

The rising shift of pharmaceutical and biotechnology firms towards the development of medications for chronic diseases such as cancer, diabetes, and cardiovascular and among others have created ample growth opportunities for players in the market. Moreover, biologic have become a larger part of product pipelines of several drug developers, which could affect market growth positively over the forecast period. For instance, there are around 2,500 injectable products are in the developmental stage. Moreover, rising product patent expiries of several blockbusters in recent times expected to propel market growth over the forecast period. For instance, in 2015, Teva Pharmaceutical Industries Ltd. lost the patent for its top-selling multiple sclerosis drug Copaxone.

How operational and installation cost effects the sterile injectable market?

Several industry experts noted that the cost of establishing sterile injectable plants is significantly higher viz-a-viz non-sterile manufacturing plants owing to stringent aseptic requirements and complex manufacturing process; this has led to the consolidation of the industry by backward and forward integration. Moreover, competition from low-cost manufacturers, value chain integration coupled with high entry barrier for new players in the sterile injectable market expect impact market growth negatively over the forecast period.

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-sterile-injectables-market/#ulp-c654SbFYO64MsOhu


North America accounts for larger market revenue share in global sterile injectable market

North America leads the global sterile injectable market in terms of revenue in 2016. Regions such as Asia Pacific and Europe presented better growth opportunities for the market players owing to conducive business policies and increased local production generic injectable. For instance, in 2013, Mylan Inc. completed the acquisition of the Agila injectables businesses from Strides Arcolab Limited.

Competition Assessment

Key players profiled in the global sterile injectable market include:
• AbbVie Inc. (U.S)
• Amgen Inc. (U.S)
• AstraZeneca plc (U.K)
• Baxter International Inc. (U.S)
• Eli Lilly and Company (U.S)
• GILEAD SCIENCES, INC. (U.S)
• GlaxoSmithKline plc. (U.K)
• Johnson & Johnson Services, Inc. (U.S)
• Merck & Co., Inc. (U.S)
• Novo Nordisk A/S (Denmark)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S)
• F. Hoffmann-La Roche AG (Switzerland)
• Sanofi (France)
Market players are focusing on mergers and acquisitions to improve their market position in sterile injectable market. For instance, in 2016, Baxter International Inc. acquired Claris Injectables Limited, a wholly owned subsidiary of Claris Lifesciences Limited, for total consideration of approximately $625mn. In 2015 Pfizer Inc. acquired Hospira, Inc., world’s leading provider of injectable and infusion technologies.
Key Findings of the Report:

• Sterile injectable market expanding at 7.3% CAGR over 2017 to 2013 to reach market value of US$ 552 Bn by 2023
• Based on molecule type large molecules accounted for larger market share in 2016
• Oncology segment expected to be most lucrative market in global sterile injectable market
• Hospital pharmacies are prime channel for sterile drug distribution across the globe
• Players focusing on expanding geographic presence to garner market opportunities in developing economies
Key Features of the Report:

• The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
• The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
• The report tracks recent innovations, key developments and startup’s details that are actively working in the market
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
• The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-sterile-injectables-market/#ulp-14mlyhjMGhVjZqa3

Detailed Segmentation

By Molecule Type
• Large Molecules
• Small Molecules
Drug Type
• Monoclonal Antibodies
• Cytokines
• Insulin
• Peptide Hormones
• Blood Factors
• Vaccines
• Immunoglobulins
• Peptide Antibiotics
• Others
Disease Indication
• Cancer
• Diabetes
• Cardiovascular Diseases
• Musculoskeletal
• CNS
• Infections
• Others
Route of Administration
• Intravenous (IV)
• Intramuscular (IM)
• Subcutaneous (SC)
• Others

Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Geography
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o K
o Italy
o Spain
o Russia
o Poland
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia & New Zealand
o ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
o South Korea
o Rest of Asia-Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Venezuela
o Rest of Latin America
• Middle East and Africa (MEA)
o Gulf Cooperation Council (GCC) Countries
o Israel
o South Africa
o Rest of MEA

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-sterile-injectables-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Contact Person: Rajesh Babu
Role: Marketing Lead
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com

This release was published on openPR.